Spring Bank announces interim top-line results from first cohort of phase 2 trial
Spring Bank Pharma announced interim top-line results at 12 weeks from the first cohort of the ongoing Phase 2 trial evaluating safety, efficacy and pharmacodynamics of escalating doses of the investigational compound inarigivir co-administered with Gilead Sciences’ Vemlidy® for treatment of HBV. October 17, 2019